Shruti Bhat PhD, MBA, Lean Six Sigma Black Belt
  • Home
  • About Shruti
  • Consulting
  • Workshops
  • Patents
  • Articles
    • Case Studies
    • Innovation Portfolio Development & Patents
    • Drugs-in-the- making
    • Culture Change & Business Transformation
    • Operational Excellence, Quality & Continuous Improvement
  • Books
  • Digital
  • Blog
  • Videos
  • Contact

Top 15 drug patent losses for 2013

11/6/2012

0 Comments

 
We are in the midst of third quarter earnings reports, and they show  with stark detail what the tsunami of patent losses means to the financial  underpinning of drug-makers. It's a serious problem that will erode earnings for  years to come. Pharmaceutical researcher Evaluate Pharma estimates there are $290 billion of sales at risk from patent  expirations between this year and 2018.

Companies are trying to put the most positive spin they can on the  impact, but the effects can take your breath away. For example, Sanofi ,  suggested in their company's most recent earnings call that things are looking  up because its new full-year projection is for earnings to drop only 12% this  year, not the 15% projected earlier. Sanofi lost protection for three drugs.  Mega blockbuster Plavix, a blood thinner, alone saw sales drop 70%. 
 
And the patent cliff pain continues. In 2013, patents will expire on drugs that currently have sales of $29 billion annually. The research firm expects more than 70% of that total will be lost to generics. Falling revenue is usually tracked by a falling share price, but the firm points out that patent cliff problems, when a wave of big-ticket drugs lose protection, generally show  up several years in advance with a stalling stock price.

The implications are, of course, huge. But is it all bad? "The patent cliff is generally portrayed as a bad event for the Industry, but it may turn out to be a good event, with companies feeling liberated from the mega-blockbuster curse of replacing aging cash flow
streams."

That depends, on how companies respond. Too often, spurred by the feeling they need to raise their share price--and perhaps made overconfident by the success of aging blockbusters--they blow it. They take excess cash from those aging cash cows and overindulge on "risky, late-stage, in-process R&D assets in seemingly high-priced and speculative in-licensing deals and company
acquisitions”.

Even those companies that say they are dedicated to finding their future with R&D don't always seem to know how. Statistics points out the industry has plunked down $1.1 trillion, in the last decade on research and development--and too often with very poor results. 

So what are the drugs that top the 2013 patent expiry list?  Presented here the top 15, out of about 120, that will see patents expire next year. It is led by Eli Lilly's anxiety and depression drug Cymbalta, which last year generated $4.9 billion in sales for the company. It includes Purdue Pharma's OxyContin, which sold to the tune of $2.4 billion last year, and tails off with the Novartis osteoporosis treatment Reclast, which generated $612 million.

While the overall losses are less than this year's, which will see patent protection stripped away on about $67 billion, they will keep some companies in a vise grip of indecision. Others, perhaps, will free themselves and find their way to smart investments and drugs that provide benefits to patients and returns to shareholders.
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement

    New Book Released!

    top ten strategic decision-making tools for operational excellence

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    5S
    Agile
    Artificial Intelligence
    Automation
    Balanced Score Card
    Biotechnology
    Books
    Business Turnaround
    Case Studies
    Change Management
    Chemical Industry
    CMMI
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Food Industry
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    Nanotechnology
    Operations
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    Robotics
    Scrum
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    TQM
    Videos
    Voice Of Customer
    Workshops

    Shruti's books...

    Picture
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    Picture
    how to overcome challenges of creating effective teams
    how to lead a successful business transformation

    ​Micro-Learning
    ​Partner

    Picture

    Publishing Partner

    fast read books, business management books, health and wellness books, spiritual guidance books, best online book store

    Wellness
    ​Partner

    Picture
© Copyright 1992- 2022 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media